Expert speak: How Indian pharma companies can grow their business

In the past few years, the Indian pharmaceutical Industry (IPI) has grown at nearly 12 to 15 per cent which is a tremendous pace of growth if we compare it to that of the US or European markets. No doubt the growth of the industry will continue to be in double digits and India may rank among the top five global pharma markets by 2030. But it is also becoming difficult for domestic companies to survive in the current scenario. Along with small and mid-size firms, even a few big players have exited the business in the last five to seven years.

Big international houses are becoming more active in India – they have both money and resources to flourish in the IPI. A lot of equity transactions are happening in the marketplace – a few recent ones being those of Piramal (Abbott), Agila Specialities (Mylan) and GSK (increased its own stake). It is not only big players who want to enter the country, but also domestic players don’t see much growth in the near future despite the expected high growth in the industry. This is a pretty serious situation and must be discussed.



Tagged as: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: